Cutinase-like protein-6 of Mycobacterium tuberculosis is recognised in tuberculosis patients and protects mice against pulmonary infection as a single and fusion protein vaccine

Vaccine

Volumn 28, Issue 5, 2010, Pages 1341-1346

  Shanahan, Erin R ^a   Pinto, Rachel ^b   Triccas, James A ^b   Britton, Warwick J ^a,b   West, Nicholas P ^a  

^a CENTENARY INSTITUTE   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Boosting vaccine; Fusion protein vaccine; Tuberculosis (TB) patients

Indexed keywords

BCG VACCINE; CUTINASE LIKE PROTEIN 1; CUTINASE LIKE PROTEIN 1 6 FUSION PROTEIN; CUTINASE LIKE PROTEIN 2; CUTINASE LIKE PROTEIN 2 6 FUSION PROTEIN; CUTINASE LIKE PROTEIN 6; GAMMA INTERFERON; HYBRID PROTEIN; UNCLASSIFIED DRUG;

AEROSOL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BCG VACCINATION; CELL WALL; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNITY; MOUSE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL; SINGLE DRUG DOSE; T LYMPHOCYTE; TUBERCULOSIS;

ANIMALS; ANTIGENS, BACTERIAL; BACTERIAL PROTEINS; FEMALE; HUMANS; MALE; MICE; MYCOBACTERIUM TUBERCULOSIS; RECOMBINANT FUSION PROTEINS; T-LYMPHOCYTES; TUBERCULOSIS VACCINES; TUBERCULOSIS, PULMONARY;

EID: 74149085193     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2009.11.010     Document Type: Article

References (38)

1. Dye C. Global epidemiology of tuberculosis. Lancet 367 9514 (2006) 938-940
2. Dye C., Scheele S., Dolin P., Pathania V., and Raviglione M.C. Consensus statement. Global burden of tuberculosis: estimated incidence, prevalence, and mortality by country. WHO Global Surveillance and Monitoring Project. JAMA 282 7 (1999) 677-686
3. Colditz G.A., Berkey C.S., Mosteller F., Brewer T.F., Wilson M.E., Burdick E., et al. The efficacy of bacillus Calmette-Guerin vaccination of newborns and infants in the prevention of tuberculosis: meta-analyses of the published literature. Pediatrics 96 1 Pt 1 (1995) 29-35
4. Walker V., Selby G., and Wacogne I. Does neonatal BCG vaccination protect against tuberculous meningitis?. Arch Dis Child 91 9 (2006) 789-791
5. Fine P.E. Variation in protection by BCG: implications of and for heterologous immunity. Lancet 346 8986 (1995) 1339-1345
6. Horwitz M.A., Harth G., Dillon B.J., and Maslesa-Galic S. Recombinant bacillus Calmette-Guerin (BCG) vaccines expressing the Mycobacterium tuberculosis 30-kDa major secretory protein induce greater protective immunity against tuberculosis than conventional BCG vaccines in a highly susceptible animal model. Proc Natl Acad Sci USA 97 25 (2000) 13853-13858
7. Grode L., Seiler P., Baumann S., Hess J., Brinkmann V., Nasser Eddine A., et al. Increased vaccine efficacy against tuberculosis of recombinant Mycobacterium bovis bacille Calmette-Guerin mutants that secrete listeriolysin. J Clin Invest 115 9 (2005) 2472-2479
8. Ryan A.A., Wozniak T.M., Shklovskaya E., O'Donnell M.A., Fazekas de St Groth B., Britton W.J., et al. Improved protection against disseminated tuberculosis by Mycobacterium bovis bacillus Calmette-Guerin secreting murine GM-CSF is associated with expansion and activation of APCs. J Immunol 179 12 (2007) 8418-8424
9. Sambandamurthy V.K., Derrick S.C., Jalapathy K.V., Chen B., Russell R.G., Morris S.L., et al. Long-term protection against tuberculosis following vaccination with a severely attenuated double lysine and pantothenate auxotroph of Mycobacterium tuberculosis. Infect Immun 73 2 (2005) 1196-1203
10. Martin C., Williams A., Hernandez-Pando R., Cardona P.J., Gormley E., Bordat Y., et al. The live Mycobacterium tuberculosis phoP mutant strain is more attenuated than BCG and confers protective immunity against tuberculosis in mice and guinea pigs. Vaccine 24 17 (2006) 3408-3419
11. Weinrich Olsen A., van Pinxteren L.A., Meng Okkels L., Birk Rasmussen P., and Andersen P. Protection of mice with a tuberculosis subunit vaccine based on a fusion protein of antigen 85b and esat-6. Infect Immun 69 5 (2001) 2773-2778
12. Skeiky Y.A., Alderson M.R., Ovendale P.J., Guderian J.A., Brandt L., Dillon D.C., et al. Differential immune responses and protective efficacy induced by components of a tuberculosis polyprotein vaccine, Mtb72F, delivered as naked DNA or recombinant protein. J Immunol 172 12 (2004) 7618-7628
13. McShane H., Pathan A.A., Sander C.R., Goonetilleke N.P., Fletcher H.A., and Hill A.V. Boosting BCG with MVA85A: the first candidate subunit vaccine for tuberculosis in clinical trials. Tuberculosis (Edinburgh, Scotland) 85 1-2 (2005) 47-52
14. Skeiky Y.A., and Sadoff J.C. Advances in tuberculosis vaccine strategies. Nat Rev 4 6 (2006) 469-476
15. Andersen P. Effective vaccination of mice against Mycobacterium tuberculosis infection with a soluble mixture of secreted mycobacterial proteins. Infect Immun 62 6 (1994) 2536-2544
16. Wiker H.G., Mustafa T., Malen H., and Riise A.M. Vaccine approaches to prevent tuberculosis. Scand J Immunol 64 3 (2006) 243-250
17. Olsen A.W., Williams A., Okkels L.M., Hatch G., and Andersen P. Protective effect of a tuberculosis subunit vaccine based on a fusion of antigen 85B and ESAT-6 in the aerosol guinea pig model. Infect Immun 72 10 (2004) 6148-6150
18. West N.P., Wozniak T.M., Valenzuela J., Feng C.G., Sher A., Ribeiro J.M., et al. Immunological diversity within a family of cutinase-like proteins of Mycobacterium tuberculosis. Vaccine 26 31 (2008) 3853-3859
19. West N.P., Chow F.M., Randall E.J., Wu J., Chen J., Ribeiro J.M., et al. Cutinase-like proteins of Mycobacterium tuberculosis: characterization of their variable enzymatic functions and active site identification. FASEB J 23 6 (2009) 1694-1704
20. Weldingh K., Rosenkrands I., Jacobsen S., Rasmussen P.B., Elhay M.J., and Andersen P. Two-dimensional electrophoresis for analysis of Mycobacterium tuberculosis culture filtrate and purification and characterization of six novel proteins. Infect Immun 66 8 (1998) 3492-3500
21. Brandt L., Elhay M., Rosenkrands I., Lindblad E.B., and Andersen P. ESAT-6 subunit vaccination against Mycobacterium tuberculosis. Infect Immun 68 2 (2000) 791-795
22. Weldingh K., and Andersen P. Immunological evaluation of novel Mycobacterium tuberculosis culture filtrate proteins. FEMS Immunol Med Microbiol 23 2 (1999) 159-164
23. Sable S.B., Kumar R., Kalra M., Verma I., Khuller G.K., Dobos K., et al. Peripheral blood and pleural fluid mononuclear cell responses to low-molecular-mass secretory polypeptides of Mycobacterium tuberculosis in human models of immunity to tuberculosis. Infect Immun 73 6 (2005) 3547-3558
24. Hovav A.H., Fishman Y., and Bercovier H. Gamma interferon and monophosphoryl lipid A-trehalose dicorynomycolate are efficient adjuvants for Mycobacterium tuberculosis multivalent acellular vaccine. Infect Immun 73 1 (2005) 250-257
25. Sable S.B., Verma I., and Khuller G.K. Multicomponent antituberculous subunit vaccine based on immunodominant antigens of Mycobacterium tuberculosis. Vaccine 23 32 (2005) 4175-4184
26. Grover A., Ahmed M.F., Verma I., Sharma P., and Khuller G.K. Expression and purification of the Mycobacterium tuberculosis complex-restricted antigen CFP21 to study its immunoprophylactic potential in mouse model. Protein Expr Purif 48 2 (2006) 274-280
27. Sassetti C.M., Boyd D.H., and Rubin E.J. Genes required for mycobacterial growth defined by high density mutagenesis. Mol Microbiol 48 1 (2003) 77-84
28. Roche P.W., Triccas J.A., Avery D.T., Fifis T., Billman-Jacobe H., and Britton W.J. Differential T cell responses to mycobacteria-secreted proteins distinguish vaccination with bacille Calmette-Guerin from infection with Mycobacterium tuberculosis. J Infect Dis 170 5 (1994) 1326-1330
29. Ravn P., Demissie A., Eguale T., Wondwosson H., Lein D., Amoudy H.A., et al. Human T cell responses to the ESAT-6 antigen from Mycobacterium tuberculosis. J Infect Dis 179 3 (1999) 637-645
30. Williams A., Hatch G.J., Clark S.O., Gooch K.E., Hatch K.A., Hall G.A., et al. Evaluation of vaccines in the EU TB Vaccine Cluster using a guinea pig aerosol infection model of tuberculosis. Tuberculosis (Edinburgh, Scotland) 85 1-2 (2005) 29-38
31. Dietrich J., Andersen C., Rappuoli R., Doherty T.M., Jensen C.G., and Andersen P. Mucosal administration of Ag85B-ESAT-6 protects against infection with Mycobacterium tuberculosis and boosts prior bacillus Calmette-Guerin immunity. J Immunol 177 9 (2006) 6353-6360
32. Brandt L., Skeiky Y.A., Alderson M.R., Lobet Y., Dalemans W., Turner O.C., et al. The protective effect of the Mycobacterium bovis BCG vaccine is increased by coadministration with the Mycobacterium tuberculosis 72-kilodalton fusion polyprotein Mtb72F in M. tuberculosis-infected guinea pigs. Infect Immun 72 11 (2004) 6622-6632
33. Reed S.G., Coler R.N., Dalemans W., Tan E.V., DeLa Cruz E.C., Basaraba R.J., et al. Defined tuberculosis vaccine, Mtb72F/AS02A, evidence of protection in cynomolgus monkeys. Proc Natl Acad Sci USA 106 7 (2009) 2301-2306
34. Santosuosso M., McCormick S., Zhang X., Zganiacz A., and Xing Z. Intranasal boosting with an adenovirus-vectored vaccine markedly enhances protection by parenteral Mycobacterium bovis BCG immunisation against pulmonary tuberculosis. Infect Immun 74 8 (2006) 4634-4643
35. Vordermeier H.M., Villarreal-Ramos B., Cockle P.J., Macaulay M., Rhodes S.G., Thacker T., et al. Viral booster vaccines improve BCG-induced protection against bovine tuberculosis. Infect Immun 77 8 (2009) 3364-3373
36. Verreck F.A., Vervenne R.A., Kondova I., van Kralingen K.W., Remarque E.J., Braskamp G., et al. MVA.85A boosting of BCG and an attenuated, phoP deficient M. tuberculosis vaccine both show protective efficacy against tuberculosis in rhesus macaques. PloS One 4 4 (2009) e5264
37. Hawkridge T., Scriba T.J., Gelderbloem S., Smit E., Tameris M., Moyo S., et al. Safety and immunogenicity of a new tuberculosis vaccine, MVA85A, in healthy adults in South Africa. J Infect Dis 198 4 (2008) 544-552
38. Xing Z., McFarland C.T., Sallenave J.M., Izzo A., Wang J., and McMurray D.N. Intranasal mucosal boosting with an adenovirus-vectored vaccine markedly enhances the protection of BCG-primed guinea pigs against pulmonary tuberculosis. PloS One 4 6 (2009) e5856